Literature DB >> 9451470

Glycation of insulin results in reduced biological activity in mice.

Y H Abdel-Wahab1, F P O'Harte, A C Boyd, C R Barnett, P R Flatt.   

Abstract

Bovine insulin was glycated by in vitro incubation with 20-220 mM D-glucose for 1-48 h. The percentage of glycation was dependent on time, glucose concentration, temperature and pH, attaining values up to 28%. Glucose-lowering activities of glycated and control (non-glycated) insulin preparations were assessed in mice by intraperitoneal injection in a 39% (w/v) glucose solution (2 g/kg body weight) at doses of 0.05 and 0.25 units/kg body weight. Injection of glucose alone significantly (P < 0.001) increased plasma glucose concentrations at 30 min. Simultaneous administration of non-glycated insulin with glucose significantly decreased the 30-min glycaemic excursion (P < 0.001) in a dose-dependent manner. Glycated insulin exhibited a significant reduction (P < 0.001) in glucose-lowering activity under these conditions. The relationship between the extent of insulin glycation and glucose-lowering activity at 0.25 units/kg was assessed using five different insulin preparations glycated between 6%-28%. The insulin-induced decrease in plasma glucose at 30 min was inversely related to the extent of glycation (r = 0.99). Glycated insulin (10(-8) and 10(-6) M) also exhibited a significantly reduced (P < 0.05) ability to stimulate glucose oxidation in isolated mouse diaphragm muscle compared with non-glycated insulin. These data indicate that glycated insulin exhibits impaired biological activity which may contribute to glucose intolerance in diabetes. Further studies are required to determine if glycation of insulin occurs in man and if this process contributes to the pathogenesis of diabetes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9451470     DOI: 10.1007/s005920050086

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  14 in total

Review 1.  Risk factors preceding type 2 diabetes and cardiomyopathy.

Authors:  Shamjeet Singh; Sanjiv Dhingra; Dan D Ramdath; Sudesh Vasdev; Vicki Gill; Pawan K Singal
Journal:  J Cardiovasc Transl Res       Date:  2010-07-01       Impact factor: 4.132

2.  RAGE influences obesity in mice. Effects of the presence of RAGE on weight gain, AGE accumulation, and insulin levels in mice on a high fat diet.

Authors:  B Leuner; M Max; K Thamm; C Kausler; Y Yakobus; A Bierhaus; S Sel; B Hofmann; R-E Silber; A Simm; N Nass
Journal:  Z Gerontol Geriatr       Date:  2012-02       Impact factor: 1.281

3.  Demonstration of increased concentrations of circulating glycated insulin in human Type 2 diabetes using a novel and specific radioimmunoassay.

Authors:  J R Lindsay; A M McKillop; M H Mooney; F P M O'Harte; P M Bell; P R Flatt
Journal:  Diabetologia       Date:  2003-03-18       Impact factor: 10.122

4.  Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma.

Authors:  Feliciano Priego-Capote; Alexander Scherl; Markus Müller; Patrice Waridel; Frédérique Lisacek; Jean-Charles Sanchez
Journal:  Mol Cell Proteomics       Date:  2009-11-06       Impact factor: 5.911

Review 5.  Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Authors:  Sherman S Leung; Josephine M Forbes; Danielle J Borg
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

6.  Mass spectrometry characterization of the glycation sites of bovine insulin by tandem mass spectrometry.

Authors:  Sofia Guedes; Rui Vitorino; M Rosário M Domingues; Francisco Amado; Pedro Domingues
Journal:  J Am Soc Mass Spectrom       Date:  2009-03-13       Impact factor: 3.109

7.  Glucose binds to the insulin receptor affecting the mutual affinity of insulin and its receptor.

Authors:  Robert Root-Bernstein; Jessica Vonck
Journal:  Cell Mol Life Sci       Date:  2009-06-25       Impact factor: 9.261

8.  Optimising insulin aspart practices in a neonatal intensive care unit: a clinical and pharmaco-technical study.

Authors:  Laure-Hélène Préta; Stéphanie Genay; Cécile Malat; Natacha Carta; Mohamed Riadh Boukhris; Julie Verspieren; Pascal Odou; Laurent Storme; Bertrand Décaudin
Journal:  Eur J Pediatr       Date:  2021-04-17       Impact factor: 3.183

9.  An insulin-like modular basis for the evolution of glucose transporters (GLUT) with implications for diabetes.

Authors:  Robert Root-Bernstein
Journal:  Evol Bioinform Online       Date:  2007-10-15       Impact factor: 1.625

10.  An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes.

Authors:  Alessandra Puddu; François Mach; Alessio Nencioni; Giorgio Luciano Viviani; Fabrizio Montecucco
Journal:  Mediators Inflamm       Date:  2013-01-10       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.